BeiGene (BGNE) intends to change its name to BeOne Medicines Ltd., and will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. The company’s CUSIP number will remain unchanged. In addition, the company stock codes and stock names for The Stock Exchange of Hong Kong and the STAR Market of the Shanghai Stock Exchange will not change.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE:
- BeiGene gets FDA orphan designation in Waldenstrom macroglobulinemia treatment
- Biotech Alert: Searches spiking for these stocks today
- BeiGene announces global licensing agreement for MAT2A inhibitor
- BeiGene discloses new data in BRUKINSA, promising advancements pipeline at ASH
- BeiGene assumed with an Overweight at Morgan Stanley